Kiniksa officer Ross Moat proposes $9.75M share sale
The listed shares are associated with two restricted-stock lapses and an employee stock option exercise.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kiniksa Pharmaceuticals International, plc (KNSA) lists a proposed sale of 103,585 Class A ordinary shares for officer Ross Moat, with an approximate sale date of October 30, 2026, through Charles Schwab & Co., Inc. The reported aggregate market value is $9,753,812.00. The listed share history includes 1,735 shares from a restricted stock lapse on April 1, 2026, 4,278 shares from a restricted stock lapse on September 1, 2026, and 97,572 shares from an employee stock option exercise on October 30, 2026, identified with broker payment for cashless exercise. The remarks state that sales may occur over various dates.
Key Figures
Key Terms
Rule 144 regulatory
Restricted Stock Lapse financial
Employee Stock Option Exercise financial
Cashless Exercise financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.